6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1

Cancer Research

Volumn 74, Issue 1, 2014, Pages 243-252

  Li, Haitao ^a   Zhu, Feng ^a   Chen, Hanyong ^a   Cheng, Ka Wing ^c   Zykova, Tatyana ^a   Oi, Naomi ^a   Lubet, Ronald A ^b   Bode, Ann M ^a   Wang, Mingfu ^c   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

6 (PHENYLETHENYL)NARINGENIN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 1; NARINGENIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; EX VIVO STUDY; GASTROINTESTINAL HEMORRHAGE; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALIGNANT TRANSFORMATION; MATHEMATICAL ANALYSIS; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; FLAVANONES; HT29 CELLS; HUMANS; MALE; MICE; MICE, NUDE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892758917     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2245     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885-95.
3. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-40.
4. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
5. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
6. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
7. Camitta MG, Gabel SA, Chulada P, Bradbury JA, Langenbach R, Zeldin DC, et al. Cyclooxygenase-1 and-2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001;104:2453-8.
8. Inserte J, Molla B, Aguilar R, Traves PG, Barba I, Martin-Sanz P, et al. Constitutive COX-2 activity in cardiomyocytes confers permanent cardioprotection Constitutive COX-2 expression and cardioprotection. J Mol Cell Cardiol 2009;46:160-8.
9. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000;97:10197-202.
10. Wang D, Patel VV, Ricciotti E, Zhou R, Levin MD, Gao E, et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A 2009;106:7548-52.
11. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114:873-7.
12. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
13. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-304.
14. Gray PA, Warner TD, Vojnovic I, Del Soldato P, Parikh A, Scadding GK, et al. Effects of non-steroidal anti-inflammatory drugs on cyclooxygenase and lipoxygenase activity in whole blood from aspirinsensitive asthmatics vs healthy donors. Br J Pharmacol 2002; 137:1031-8.
15. Pedersen AK, Fitzgerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984; 311:1206-11.
16. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-8.
17. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-401.
18. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 2005;65: 3735-44.
19. Perrone MG, Scilimati A, Simone L, Vitale P. Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem 2010; 17:3769-805.
20. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal antiinflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 2011;4:1728-35.
21. Cheng KW, Wong CC, Cho CK, Chu IK, Sze KH, Lo C, et al. Trapping of phenylacetaldehyde as a key mechanism responsible for naringenin's inhibitory activity in mutagenic 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine formation. Chem Res Toxicol 2008;21:2026-34.
22. Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, et al. Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 2004;64: 3694-700.
23. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
25. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91: 609-13.
26. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997; 272:9962-70.
27. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem 2007;50:1425-41.
28. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.
29. Reddy ST, Tiano HF, Langenbach R, Morham SG, Herschman HR. Genetic evidence for distinct roles of COX-1 and COX-2 in the immediate and delayed phases of prostaglandin synthesis in mast cells. Biochem Biophys Res Commun 1999;265:205-10.
30. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
31. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 1997;94:657-62.
32. Humtsoe JO, Kramer RH. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. Oncogene 2010;29:1214-26.
33. Jachak SM. Cyclooxygenase inhibitory natural products: current status. Curr Med Chem 2006;13:659-78.
34. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-14.
35. Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003;63:4872-7.